Aptah Bio
San Carlos
About Aptah Bio
Imagine a world where age-related diseases are things of the past! That’s the potential Aptah Bio is unlocking. We are working with leading global scientists, laboratories, and the best patent attorneys to develop the next pharmaceutical blockbuster with a multi-billion dollar market value, able to impact the lives of millions of people. Aptah Bio’s compound significantly reduces age-related random RNA processing errors, thus eliminating multiple faulty RNAs and resulting toxic proteins with one compound. Its utility spans across multiple therapeutic categories, including age-related neurodegenerative diseases and cancer, areas of high unmet medical need, and significant commercial potential. As the global population ages, age-related diseases have become a significant, growing concern and socioeconomic burden, currently inadequately addressed by existing therapies. Our therapy holds the potential to address the root cause of many of these age-related dysfunctional proteins and the diseases they cause.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $4.5M
- Funding stage: Seed
- Last round: Seed (Jan 2021)
- Website: aptah-bio.com
- Phone: +16507326177
Industries & Categories
Bioinformatics, Biotechnology, Life Science, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/aptah-bio-110880 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.